EXENATIDE ( DrugBank: Exenatide )

6 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	10
17	多系統萎縮症	2
72	下垂体性ADH分泌異常症	1
78	下垂体前葉機能低下症	2
193	プラダー・ウィリ症候群	3
233	ウォルフラム症候群	1

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04269642 (ClinicalTrials.gov)	March 19, 2020	13/1/2020	SR-Exenatide (PT320) to Eveluate Efficacy and Safety in Patients With Early Parkinson's Disease	Phase IIa Study to Evaluate the Efficacy and Safety of Subcutaneous SR-Exenatide (PT320) in Patients With Early Parkinson's Disease	Early Parkinson's Disease	Drug: PT320 2.0mg Placebo;Drug: PT320 2.0 mg;Drug: PT320 2.5 mg	Peptron, Inc.	NULL	Active, not recruiting	40 Years	75 Years	All	99	Phase 2	Korea, Republic of
2	NCT04305002 (ClinicalTrials.gov)	January 21, 2020	20/2/2020	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on Disease Progression in Early Parkinson's Disease	Parkinson Disease	Drug: Exenatide;Drug: Placebo	Center for Neurology, Stockholm	Karolinska Institutet	Active, not recruiting	25 Years	80 Years	All	60	Phase 2	Sweden
3	NCT04232969 (ClinicalTrials.gov)	January 20, 2020	10/1/2020	Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	A Randomised, Double Blind, Parallel Group, Placebo Controlled, Phase 3 Trial of Exenatide Once Weekly Over 2 Years as a Potential Disease Modifying Treatment for Parkinson's Disease	Parkinson's Disease	Drug: Exenatide extended release 2mg (Bydureon)	University College, London	NULL	Active, not recruiting	25 Years	80 Years	All	194	Phase 3	United Kingdom
4	EUCTR2019-000732-26-SE (EUCTR)	23/10/2019	07/05/2019	Exenatide Treatment in Parkinson's Disease	Effect of Exenatide on disease progression in early Parkinson's disease.	Parkinson's disease;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Bydureon 2 mg powder and solvent for prolonged-release suspension Product Name: BYDUREON INN or Proposed INN: EXENATIDE	Stockholm Health Care Services	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	60	Phase 2	Sweden
5	EUCTR2018-003028-35-GB (EUCTR)	04/09/2019	15/11/2019	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease.	A randomised, double blind, parallel group, placebo controlled, Phase 3 trial of exenatide once weekly over 2 years as a potential disease modifying treatment for Parkinson's disease. - Phase 3 Trial of exenatide for Parkinson’s disease	Parkinson's disease MedDRA version: 21.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide	University College London Comprehensive Clinical Trial Unit	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	200	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): no	United Kingdom
6	NCT03456687 (ClinicalTrials.gov)	June 5, 2018	1/3/2018	Effects of Exenatide on Motor Function and the Brain	Effects of Exenatide on Motor Function and the Brain	Parkinson's Disease	Drug: Exenatide	University of Florida	National Institute of Neurological Disorders and Stroke (NINDS)	Completed	40 Years	77 Years	All	5	Phase 1	United States
7	NCT01971242 (ClinicalTrials.gov)	June 2014	23/10/2013	Trial of Exenatide for Parkinson's Disease	A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease	Parkinson's Disease	Drug: Exenatide;Other: Placebo	University College, London	NULL	Completed	25 Years	75 Years	Both	60	Phase 2	United Kingdom
8	EUCTR2013-003363-64-GB (EUCTR)	03/04/2014	11/03/2014	Trial of Exenatide for Parkinson's disease	A randomised, double blind, placebo controlled, single centre, 60 week trial of Exenatide once weekly for the treatment of moderate severity Parkinson’s disease. - Exenatide-PD	Parkinson's Disease MedDRA version: 16.1;Level: LLT;Classification code 10013113;Term: Disease Parkinson's;System Organ Class: 100000004852;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Bydureon Product Name: Exenatide INN or Proposed INN: exenatide	University College London	NULL	Not Recruiting			Female: yes Male: yes	60	Phase 2	United Kingdom
9	NCT01174810 (ClinicalTrials.gov)	July 2010	2/8/2010	Exendin-4 as a Treatment for Parkinson's Disease - Pilot Study	An Open Label, Single Site, 12 Month, Phase II, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exendin-4 (Exenatide) in the Treatment of Patients With Moderate Severity Parkinson's Disease.	Parkinson's Disease	Drug: Exenatide	University College, London	NULL	Active, not recruiting	45 Years	70 Years	Both	40	Phase 2	United Kingdom
10	EUCTR2009-018137-37-GB (EUCTR)	14/04/2010	18/03/2010	An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial	An open label, single site, 12 month, Phase II, randomised controlled trial evaluating the safety and efficacy of Exendin-4 (Exenatide) in the treatment of patients with moderate severity Parkinson's disease. - Exendin-4 as a treatment for Parkinson's disease- pilot trial	Parkinson's disease MedDRA version: 14.1;Level: PT;Classification code 10061536;Term: Parkinson's disease;System Organ Class: 10029205 - Nervous system disorders	Trade Name: Byetta 5 micrograms Product Name: Exenatide 5 micrograms Trade Name: Exenatide 10 micrograms Product Name: Exenatide 10 micrograms	University College London	NULL	Not Recruiting			Female: yes Male: yes	40	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	United Kingdom

先頭へ

17. 多系統萎縮症

臨床試験数 : 119 / 薬物数 : 138 - (DrugBank : 44) / 標的遺伝子数 : 59 - 標的パスウェイ数 : 111

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04431713 (ClinicalTrials.gov)	September 16, 2020	29/5/2020	Exenatide Once-weekly as a Treatment for Multiple System Atrophy	An Open Label, Single Site, 48 Week, Randomised Controlled Trial Evaluating the Safety and Efficacy of Exenatide Once-weekly in the Treatment of Patients With Multiple System Atrophy	Multiple System Atrophy	Drug: Exenatide Pen Injector [Bydureon]	University College, London	NULL	Recruiting	30 Years	80 Years	All	50	Phase 2	United Kingdom
2	EUCTR2020-000122-26-GB (EUCTR)	11/05/2020	06/04/2020	Exenatide once-weekly as a treatment for Multiple System Atrophy.	A Phase IIa, open label, single-site, 48 week randomised controlled trial evaluating the safety and efficacy of Exenatide once-weekly in the treatment of patients with Multiple System Atrophy - Exenatide once-weekly as a treatment for Multiple System Atrophy.	Multiple System Atrophy MedDRA version: 21.1;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders	Trade Name: Bydureon Product Name: Bydureon INN or Proposed INN: Exenatide	University College London (UCL)	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 2	United Kingdom

72. 下垂体性ADH分泌異常症

臨床試験数 : 41 / 薬物数 : 27 - (DrugBank : 8) / 標的遺伝子数 : 7 - 標的パスウェイ数 : 10

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04897802 (ClinicalTrials.gov)	September 13, 2021	17/5/2021	Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)	Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)	Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin Deficiency	Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Instituto de Salud Carlos III	Recruiting	18 Years	65 Years	All	52	Phase 4	Spain

78. 下垂体前葉機能低下症

臨床試験数 : 492 / 薬物数 : 341 - (DrugBank : 47) / 標的遺伝子数 : 45 - 標的パスウェイ数 : 100

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04897802 (ClinicalTrials.gov)	September 13, 2021	17/5/2021	Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)	Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)	Hypopituitarism;Central Diabetes Insipidus;Panhypopituitarism;Psychological Disorder;Social Isolation;Hypothalamic Diseases;Pituitary Diseases;Oxytocin Deficiency	Drug: Experimental: GLP1-RA (exenatide) administration;Drug: Control: Placebo administration	Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau	Instituto de Salud Carlos III	Recruiting	18 Years	65 Years	All	52	Phase 4	Spain
2	EUCTR2020-004115-27-ES (EUCTR)	10/05/2021	01/09/2021	Identification and clinical relevance of oxytocin deficient status: GLP1 study	Identification and clinical relevance of oxytocin deficient status: randomized, crossover, placebo-controlled pathophysiological pilot study: GLP1 study	Hypopituitarism;Therapeutic area: Diseases [C] - Hormonal diseases [C19]	Trade Name: Byetta INN or Proposed INN: EXENATIDE	Institut de Recerca Hospital de la Santa Creu i Sant Pau - IIB Sant Pau	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	52	Phase 2	Spain

193. プラダー・ウィリ症候群

臨床試験数 : 113 / 薬物数 : 111 - (DrugBank : 26) / 標的遺伝子数 : 48 - 標的パスウェイ数 : 102

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01444898 (ClinicalTrials.gov)	March 2012	27/9/2011	Effects of Exenatide on Overweight Adolescents With Prader-Willi Syndrome	Effects of Exenatide on Obesity and Appetite in Overweight Patients With Prader-Willi Syndrome	Prader-Willi Syndrome	Drug: Exenatide	Children's Hospital Los Angeles	NULL	Completed	13 Years	20 Years	All	10	N/A	United States
2	EUCTR2010-023179-25-GB (EUCTR)	13/09/2011	27/07/2011	Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi Syndrome	Effects of exenatide on appetite and ghrelin levels in patients with Prader-Willi Syndrome - Effects of exenatide on appetite and ghrelin in Prader-Willi Syndrome	Ghrelin levels in patients with Prader Willi Syndrome and healthy controls and response of ghrelin levels to a single exenatide injection compared with placebo (0.9% sodium chloride) injection. MedDRA version: 14.0;Level: PT;Classification code 10036476;Term: Prader-Willi syndrome;System Organ Class: 10010331 - Congenital, familial and genetic disorders	Trade Name: Byetta Product Name: Byetta Product Code: EU/1/06/362/003: 5µg (1 pen) INN or Proposed INN: exenatide	Aintree University Hospital NHS Foundation Trust	UNIVERSITY OF LIVERPOOL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes			United Kingdom
3	NCT00551343 (ClinicalTrials.gov)	October 2007	29/10/2007	Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome	Contribution of a GLP-1 Agonist to Appetite Regulation, Metabolism and Body Composition in Subjects With Prader-Willi Syndrome.	Prader-Willi Syndrome	Drug: Exenatide	Garvan Institute of Medical Research	NULL	Completed	18 Years	45 Years	All	20	N/A	Australia

233. ウォルフラム症候群

臨床試験数 : 11 / 薬物数 : 17 - (DrugBank : 8) / 標的遺伝子数 : 12 - 標的パスウェイ数 : 41

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01302327 (ClinicalTrials.gov)	March 2011	22/2/2011	GLP Analogs for Diabetes in Wolfram Syndrome Patients		Diabetes Mellitus Associated With Genetic Syndrome;Wolfram Syndrome	Drug: Exenatide	Hadassah Medical Organization	NULL	Not yet recruiting	18 Years	N/A	Both	10	N/A	NULL

先頭へ